These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 7388357

  • 1. Prostatic cancer: the response to treatment dilemma.
    Br Med J; 1980 Mar 29; 280(6218):883-4. PubMed ID: 7388357
    [No Abstract] [Full Text] [Related]

  • 2. [Importance of serum acid phosphatase for the prognosis of prostatic carcinoma].
    Breitwieser P, Nöske HD.
    Z Urol Nephrol; 1971 Apr 29; 64(4):249-56. PubMed ID: 5094006
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
    Edsmyr F, Esposti PL, Andersson L.
    Scand J Urol Nephrol Suppl; 1980 Apr 29; 55():139-42. PubMed ID: 6938017
    [Abstract] [Full Text] [Related]

  • 5. Prostatic cancer: diagnosis and prognosis.
    Karr JP, Slack NH, Murphy GP.
    Compr Ther; 1980 Oct 29; 6(10):34-41. PubMed ID: 7449363
    [No Abstract] [Full Text] [Related]

  • 6. [Rate of survival in prostatic cancer with bone metastasis].
    Kuntz D, Ryckewaert A.
    Rev Fr Etud Clin Biol; 1969 Oct 29; 14(6):609-13. PubMed ID: 5824263
    [No Abstract] [Full Text] [Related]

  • 7. Prostatic adenocarcinoma of ductal origin.
    Dube VE, Farrow GM, Greene LF.
    Cancer; 1973 Aug 29; 32(2):402-9. PubMed ID: 4124700
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [The role of PSA in prostatic adenocarcinoma].
    Manca GP.
    Minerva Med; 1990 Apr 29; 81(4):261-4. PubMed ID: 1692981
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Contribution on the clinical aspects of prostatic carcinoma].
    Sladczyk E.
    Z Arztl Fortbild (Jena); 1967 Jul 01; 61(13):657-60. PubMed ID: 5598256
    [No Abstract] [Full Text] [Related]

  • 12. [Semeiological value of so-called prostatic tartrate-labile acid phosphatases. (Critical study of 500 medical records)].
    von Niederhäusern W, Tuchschmid D.
    Ann Urol (Paris); 1970 Sep 01; 4(3):205-11. PubMed ID: 5472678
    [No Abstract] [Full Text] [Related]

  • 13. Basic diagnostic methods of clinical evaluation of the advancement of prostatic carcinoma.
    Ploch R.
    Pol Med J; 1972 Sep 01; 11(4):968-76. PubMed ID: 5078721
    [No Abstract] [Full Text] [Related]

  • 14. A case report of a high serum acid phosphatase level in metastatic prostatic adenocarcinoma.
    Sullivan H, Murthy NR.
    J Urol; 1971 Sep 01; 106(3):404. PubMed ID: 5097194
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Prognosis and treatment of prostatic carcinoma].
    Klug W.
    Zentralbl Chir; 1968 Mar 09; 93(10):362-6. PubMed ID: 5674208
    [No Abstract] [Full Text] [Related]

  • 17. Letter: High serum-acid-phosphatase levels.
    Osborne MP, Sanderson FM.
    Lancet; 1973 Oct 06; 2(7832):803. PubMed ID: 4126514
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alkaline and acid phosphatase determinations in bone disease.
    Van Lente F.
    Orthop Clin North Am; 1979 Apr 06; 10(2):437-50. PubMed ID: 36589
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.